Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

151.33 +1.72 (+1.15%)
Official Closing Price Updated: 7:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
99 100 Next >
Biden Administration Targets $6B Savings Through Medicare Drug Price Negotiations
Medicare drug price negotiations, enabled by the Inflation Reduction Act, are set to save the U.S. government $6 billion. 
Via Benzinga
Topics Economy
Exposures Interest Rates
CrowdStrike: What's Ahead For Cybersecurity Player In The Wake Of Its Corporate Crisis
After it botched a cybersecurity software update, CrowdStrike stock is paying the price. A crisis management challenge lies ahead. 
Via Investor's Business Daily
Nvidia Looks To Disrupt The Health Care Industry With AI
Nvidia is a dominant force in the artificial intelligence revolution. Now its computing platforms are disrupting the health care industry. 
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence
7 Recession-Resistant Stocks to Hold Onto for Dear Life in 2024
These seven recession-resistant stocks offer stability and potential growth even in challenging economic conditions. 
Via InvestorPlace
Looking Into Johnson & Johnson's Recent Short Interest
Via Benzinga
Exploring NYSE:JNJ's dividend characteristics.
Why the dividend investor may take a look at JOHNSON & JOHNSON (NYSE:JNJ). 
Via Chartmill
Looking At Johnson & Johnson's Recent Unusual Options Activity
Via Benzinga
Comparative Study: Johnson &amp; Johnson And Industry Competitors In Pharmaceuticals Industry
Via Benzinga
7 Dependable Dividend Stocks for Long-Term Income
Explore the best dividend stocks for long-term income excelling in the healthcare, retail, tobacco and home improvement markets. 
Via InvestorPlace
Long Covid Remains Diagnostic Mystery, Diagnosis Remains Elusive; National Institutes of Health-Funded Study Shows
A recent NIH study reveals no clear diagnostic test for Long Covid, highlighting ongoing challenges in identifying and treating the condition affecting millions of Americans. Researchers continue to... 
Via Benzinga
Exposures COVID-19
J&J Moves Closer to Resolving Baby Powder Lawsuits, 75% of Plaintiffs Support $6.5B Settlement
Johnson & Johnson secures over 75% support for a $6.5 billion settlement plan to resolve thousands of lawsuits over claims that its talc-based baby powder caused cancer. The company faces ongoing legal... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
3 Blue-Chip Stocks to Buy on the Dip: August 2024
These blue-chip stocks are well-positioned to provide positive returns to investors due to their high growth potential. 
Via InvestorPlace
Medicare Costs For Johnson & Johnson's Psoriasis Drug Stelara Double When Obtained at Pharmacies
Medicare beneficiaries face higher costs for Johnson & Johnson's Stelara due to a shift in coverage from Part B to Part D. The OIG report shows a nearly tenfold increase in Medicare spending on... 
Via Benzinga
2 Healthcare Stocks to Buy Hand Over Fist in August
These longtime winners still have a lot to offer. 
Via The Motley Fool
3 High-Yield Dividend Stocks to Buy and Hold Forever
Dividends remain one of the best long-term avenues to generating wealth. Here are three stocks you can buy and hold forever. 
Via The Motley Fool
Nasdaq Sell-Off: 5 Unstoppable Stocks to Buy That Can Protect Your Principal and Grow Your Wealth in an Unpredictable Market
Five exceptionally safe, time-tested stocks have the necessary tools to make their shareholders richer. 
Via The Motley Fool
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Reports on ‘Synergistic Effect’ of Lead Compound Plus GLP-1 in AD Treatment Model
Via Investor Brand Network
The 3 Best Dividend Aristocrats to Buy for Sustainable Income: August 2024
Explore the best dividend payouts from leading companies for sustainable, steady and growing income streams. 
Via InvestorPlace
3 Dividend Growth Stocks to Buy Hand Over Fist in August
There are blue-chip bargains paying large and growing dividends in the healthcare space. 
Via The Motley Fool
Alzheimer’s Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
EQNX::TICKER_START (NYSE:ANVS),(NYSE:MRK),(NASDAQ:SNY),(NYSE:JNJ),(NYSE:NVS) EQNX::TICKER_END 
Via FinancialNewsMedia
3 Dividend Growth Stocks to Accumulate on Dips: August Edition
These three dividend growth stocks are among the best options for long-term investors seeking reliable total returns in this current market. 
Via InvestorPlace
The Market's Excessive Recession Fears
Today's Research Daily features a comment on updated research reports on 16 major stocks, including Johnson & Johnson, T-Mobile US, Inc., and Marsh & McLennan Companies, Inc., as well as a micro-cap... 
Via Talk Markets
Topics Economy
Exposures Economy
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
From FN Media Group LLC
Via GlobeNewswire
Large Cap Biopharma And Healthcare, A Port In A Storm
Healthcare and biopharma show nice gains in a volatile week. 
Via Talk Markets
3 Defensive Stocks Weathering the Market Storm
Despite last week's market downturn, JNJ, KO, and PG posted gains, demonstrating resilience and potentially serving as defensive safe-haven investments. 
Via MarketBeat
Topics Economy Stocks
Exposures Economy US Equities
The S&P 500 Had Its Worst July in a Decade. Should You Really Buy Stocks Now?
It's key to take a long-term view. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Prediction: 2 Stocks That Will Be Worth More Than Johnson & Johnson 10 Years From Now
These two healthcare companies have far more upside potential than Johnson & Johnson. 
Via The Motley Fool
Forget Johnson & Johnson: Another Healthcare Giant Is a Much Better Bet for Growth
Abbott Laboratories' growth rate may look comparable to Johnson & Johnson's, but in the long run it could become much higher. 
Via The Motley Fool
Bargain-Hunters Paradise: 7 Value Stocks That Are Too Cheap to Ignore
These cheap value stocks are priced right for any bargain hunters seeking deals in the market at the moment. 
Via InvestorPlace
7 Leading MedTech Stocks for Next-Gen Health Solutions
With healthcare innovations promising to deliver groundbreaking solutions, these MedTech stocks should be on your radar. 
Via InvestorPlace
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback